8-K: Mersana Therapeutics Reports Positive Interim Phase 1 Clinical Data for Emi-Le at ASCO 2025, Highlighting Efficacy in Difficult-to-Treat Cancers

Mersana Therapeutics announced additional positive interim Phase 1 clinical data for its B7-H4-directed ADC, Emi-Le, demonstrating encouraging objective response rates and a differentiated safety profile in various advanced cancers, including triple-negative breast cancer and adenoid cystic carcinoma.

Summary

• Mersana Therapeutics presented additional positive interim Phase 1 clinical data for Emi-Le (emiltatug ledadotin; XMT-1660), its B7-H4-directed Dolasynthen antibody-drug conjugate (ADC), at the 2025 ASCO Annual Meeting.
• The data, with a March 8, 2025 cut-off, focused on dose escalation and backfill cohorts in patients with triple-negative breast cancer (TNBC), hormone-receptor-positive/HER2-negative breast cancer, ovarian cancer, endometrial cancer, and adenoid cystic carcinoma type 1 (ACC-1).
• A 31% confirmed objective response rate (ORR) (8/26) was observed across all enrolled tumor types with B7-H4 high tumor expression (>=70% tumor proportion score) receiving intermediate Emi-Le doses (38.1-67.4 mg/m2).
• In the subset of patients with 4 prior lines of therapy, a 44% confirmed ORR (7/16) was achieved.
• For ACC-1 patients, a 56% ORR (5/9) was reported, and the median progression-free survival (PFS) had not yet been reached as of the data cut-off, significantly contrasting with the reported median PFS of 2-3 months for this aggressive cancer.
• A 50% ORR (2/4) was observed in evaluable endometrial cancer patients with B7-H4 high tumor expression receiving intermediate doses.
• In B7-H4 high TNBC patients with 4 prior treatment lines (n=7), ORR was 29% (2/7), median PFS was 16.0 weeks, and median OS was not reached.
• In contrast, B7-H4 low TNBC patients with 4 prior treatment lines (n=11) showed 0% ORR (0/11), median PFS of 6.4 weeks, and median OS of 5.7 months.
• Emi-Le was generally well tolerated; common treatment-related adverse events (TRAEs) included transient AST increase (44%), proteinuria (40%), low-grade fatigue (33%), and low-grade nausea (31%).
• Grade 3 TRAEs in 5% or more of patients were AST increase (17%), proteinuria (14%), and anaemia (6%).
• TRAEs led to discontinuation in 3.5% of patients, dose reduction in 16.3%, and dose delay in 23.4%.
• Notably, no dose-limiting treatment-related neutropenia, neuropathy, ocular toxicity, interstitial lung disease, or thrombocytopenia were reported, which the company believes differentiates Emi-Le from many other ADCs.
• The dose expansion portion of the Phase 1 trial is ongoing, enrolling TNBC patients who have received one to four prior treatment lines, including at least one topoisomerase-1 inhibitor ADC.

Sentiment

Score: 8

Explanation: The document reports positive interim Phase 1 clinical data for Emi-Le, showing encouraging efficacy in difficult-to-treat cancers like ACC-1 and heavily pretreated TNBC, coupled with a differentiated and generally well-tolerated safety profile. This progress, along with Fast Track designations, indicates strong potential for the drug candidate.

Positives

• Emi-Le demonstrated a 31% confirmed objective response rate (ORR) across B7-H4 high tumors at intermediate doses, indicating promising efficacy.
• A higher 44% confirmed ORR was observed in heavily pretreated patients (4 prior lines of therapy), addressing a population with high unmet medical need.
• A significant 56% ORR was achieved in Adenoid Cystic Carcinoma (ACC-1), a rare and aggressive cancer with no approved therapies, where the median progression-free survival (PFS) had not yet been reached, substantially exceeding the typical 2-3 month PFS for this condition.
• Emi-Le exhibited a generally well-tolerated safety profile, notably lacking dose-limiting neutropenia, neuropathy, ocular toxicity, interstitial lung disease, or thrombocytopenia, which differentiates it from many other ADCs.
• The U.S. Food and Drug Administration (FDA) has granted two Fast Track designations to Emi-Le for advanced/metastatic triple-negative breast cancer and advanced/metastatic HER2 low/negative breast cancer post-topo-1 ADC, recognizing its potential to address unmet medical needs.

Negatives

• Emi-Le showed no objective responses (0% ORR) in B7-H4 low TNBC patients (0/11), indicating that B7-H4 expression is critical for efficacy.
• The median progression-free survival (PFS) of 6.4 weeks and median overall survival (OS) of 5.7 months in B7-H4 low TNBC patients were relatively short.
• Despite a generally well-tolerated profile, some Grade 3 treatment-related adverse events (TRAEs) were observed, including AST increase (17%), proteinuria (14%), and anaemia (6%).
• TRAEs led to dose discontinuation in 3.5% of patients, dose reduction in 16.3%, and dose delay in 23.4% of patients, suggesting some manageability challenges.

Risks

• Uncertainties inherent in research and development, and in the advancement, progression, and completion of clinical trials.
• Risk of delays in patient enrollment in the Phase 1 clinical trial of Emi-Le.
• Risk that outcomes of preclinical studies may not be predictive of clinical trial results.
• Risk that initial or interim results from a clinical trial may not be predictive of the final results of the trial or the results of future trials.
• Risk that clinical trial data may not support regulatory applications or approvals.
• Risk that Mersana may not realize the intended benefits of its platforms, technology, and collaborations.

Future Outlook

Mersana Therapeutics is currently conducting the dose expansion portion of its Phase 1 clinical trial of Emi-Le, focusing on patients with triple-negative breast cancer who have received one to four prior treatment lines, including at least one topoisomerase-1 inhibitor ADC. The company believes Emi-Le is uniquely suited to address the high unmet medical need in this specific TNBC population and sees broader development potential in other B7-H4-expressing tumor types.

Management Comments

• "We are excited to share additional interim data in an oral presentation at ASCO." Martin Huber, M.D., President and Chief Executive Officer of Mersana Therapeutics.
• "The results from our dose escalation and backfill cohorts led us to focus our initial expansion work on patients with TNBC who have previously been treated with a topoisomerase-1 inhibitor ADC, a population with high unmet need that we believe Emi-Le may be uniquely suited to address within the B7-H4 ADC field." Martin Huber, M.D., President and Chief Executive Officer of Mersana Therapeutics.
• "We also continue to be encouraged by the activity observed in other B7-H4-expressing tumor types, demonstrating Emi-Le’s broader development potential." Martin Huber, M.D., President and Chief Executive Officer of Mersana Therapeutics.
• "The clinical activity observed for emiltatug ledadotin across all enrolled tumor types is encouraging, and its safety and tolerability profile appears differentiated from many other ADCs." Antonio Giordano, MD, Ph.D., Assistant Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute.
• "The objective responses were particularly notable in patients with late-stage triple-negative breast cancer who were previously treated with topoisomerase-1 inhibitors and in patients with ACC-1, both of which are aggressive and difficult-to-treat cancers with high unmet need." Antonio Giordano, MD, Ph.D.

Industry Context

The oncology sector, particularly the development of Antibody-Drug Conjugates (ADCs), is a highly active and competitive area within the biopharmaceutical industry. Mersana's focus on B7-H4 as a novel target for ADCs, combined with a differentiated safety profile (absence of common ADC toxicities like neutropenia or neuropathy), positions Emi-Le as a potentially significant contender. The strong responses in difficult-to-treat cancers like triple-negative breast cancer (TNBC) and adenoid cystic carcinoma (ACC-1), where unmet medical needs are substantial and existing therapies are limited or non-existent, highlight Emi-Le's potential to address critical gaps in cancer treatment. The Fast Track designations from the FDA underscore the recognized urgency and potential benefit of this therapy.

Comparison to Industry Standards

• For Adenoid Cystic Carcinoma (ACC-1), where no approved therapies exist and median progression-free survival (PFS) is typically 2-3 months, Emi-Le's median PFS had not yet been reached as of the data cut-off, indicating a potentially significant improvement over the natural course of the disease.
• The company explicitly states that Emi-Le's safety profile, characterized by the absence of dose-limiting neutropenia, neuropathy, ocular toxicity, interstitial lung disease, or thrombocytopenia, differentiates it from many other approved and clinical-stage ADCs, suggesting a competitive advantage in tolerability.
• The focus on heavily pretreated triple-negative breast cancer (TNBC) patients, including those who have received prior topoisomerase-1 inhibitor ADCs, targets a patient population with high unmet need where current treatment options are often exhausted or provide limited benefit.

Stakeholder Impact

• Shareholders: The positive clinical data could enhance investor confidence and potentially lead to an increase in the company's stock value.
• Patients: Emi-Le offers a promising new treatment option for patients suffering from aggressive and difficult-to-treat cancers, particularly those with high unmet medical needs like ACC-1 and heavily pretreated TNBC.
• Employees: Positive clinical trial results can boost morale and validate the company's research and development efforts, potentially attracting new talent.
• Healthcare Providers: The differentiated safety profile and efficacy in challenging indications could make Emi-Le an attractive option for oncologists once approved.

Next Steps

• Continue the dose expansion portion of the Phase 1 clinical trial of Emi-Le in patients with triple-negative breast cancer (TNBC) who have received one to four prior treatment lines, including at least one prior topoisomerase-1 inhibitor ADC.
• Further evaluate Emi-Le in two dose expansion cohorts: Dose A (67.4 mg/m2 Q4W) and Dose B (80 mg/m2 Q4W with a loading dose).

Key Dates

Recommendation

Keywords

Mersana Therapeutics, Emi-Le, XMT-1660, Antibody-Drug Conjugate, ADC, B7-H4, Dolasynthen, Phase 1 Clinical Trial, Oncology, Cancer Treatment, Triple-Negative Breast Cancer, TNBC, Adenoid Cystic Carcinoma, ACC-1, Ovarian Cancer, Endometrial Cancer, ASCO Annual Meeting, Clinical Data, Biopharmaceutical, Drug Development, Fast Track Designation